MCT-Therapeutics

MCT-Therapeutics is a biotechnology company focused on developing innovative cancer treatments by targeting monocarboxylate transporters (MCTs). As a spin-off from the University of Minho in Portugal, the company leverages deep expertise in cancer metabolism to disrupt the transport of lactate, a key fuel and signaling molecule for aggressive tumor cells. Their primary research programs involve the development of small molecule inhibitors for MCT1 and MCT4, which are often overexpressed in various solid tumors. By inhibiting these transporters, MCT-Therapeutics aims to starve cancer cells and improve patient outcomes in oncology. The company's approach targets the metabolic symbiosis within the tumor microenvironment, potentially offering a new class of therapeutics for hard-to-treat cancers.